REG - Diaceutics PLC - Data to be Presented at 2024 ASCO Annual Meeting

DiaceuticsAnnouncement

28/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240528:nRSb9625Pa&default-theme=true

RNS Number : 9625P  Diaceutics PLC  28 May 2024

Diaceutics Announces Data to be Presented at 2024 ASCO Annual Meeting

Belfast and London, 28 May 2024 - Diaceutics PLC (AIM: DXRX), a leading
technology and solutions provider to the pharma and biotech industry, today
announced the acceptance of a poster and abstract for presentation at the 2024
American Society of Clinical Oncology (ASCO) Annual Meeting, which will be
held in Chicago 31 May through 4 June 2024.

The poster presentation, titled, "Effect of real time data-driven physician
engagement on appropriate precision oncology testing", provides insight into
precision medicine and addresses the gap between potential therapy eligibility
and actual patient identification. By leveraging real-time data and
personalized digital engagement with physicians, Diaceutics successfully
increased biomarker testing rates and identified more patients eligible for
precision therapies. This highlights the pivotal role of data-driven
strategies in bridging clinical practice gaps and optimizing patient care
pathways.

The online publication, titled, "NTRK positivity and conversion to appropriate
personalized treatment is still a barrier", will highlight the challenges in
accessing targeted treatments for rare cancer biomarkers like NTRK
alterations. Despite the effectiveness of drugs like Entrectinib and
Larotrectinib, the Diaceutics study shows that only a small percentage of
patients with NTRK alterations receive related treatments. This indicates a
need for improved strategies to ensure patients can benefit from personalized
therapies, underscoring the importance of innovative approaches in
diagnostics, healthcare delivery and stakeholder engagement.

Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, commented:
"The data we will present at this year's ASCO further validates the critical
link between data analysis and actionable insights. As we navigate through the
landscape of clinical practice gaps, our mission remains clear, to drive
innovation, foster collaboration, and ultimately ensure that every patient
receives the tailored treatment they deserve. This commitment not only fuels
our growth but also underscores our dedication to maximizing the economic
viability of precision medicine, laying the groundwork for sustainable
investment and transformative impact in healthcare."

This invitation to present the Company's research at one of the most
influential meetings relating to pressing challenges within oncology, further
solidifies Diaceutics' dedication to bridging clinical practice gaps, as they
continue to lay the foundation for strategic investment opportunities that
align with the evolving landscape of precision medicine.

Diaceutics will also be hosting an informal networking reception alongside
KPMG and their combined Pharma customers which will provide an excellent
opportunity for networking and discussion within the oncology community.

Details of the abstracts are as follows:

 Poster presentation Title:  Effect of real time data-driven physician engagement on appropriate precision
                             oncology testing
 Authors:                    Ying Liu, Howard L. McLeod, Jeff Schreir, Nirmala Bhogal, Jordan Clark, Eve
                             Thompson, Arun Rompicherla, Gemma Little, Joshua McKenna, Anjum Ismail, Sarah
                             Varghese, Bethany Michelle Slifko

 Online publication Title:   NTRK positivity and conversion to appropriate personalized treatment is still
                             a barrier
 Authors:                    Bethany Michelle Slifko, Howard L. McLeod, Wendy Moore, Ines Abrunhosa Amaral
                             and Susanne Munksted

 

Information about the 2024 ASCO Annual Meeting may be accessed via the
following website: https://conferences.asco.org/am/registration
(https://conferences.asco.org/am/registration) .

Enquiries:

 Diaceutics PLC
 Ryan Keeling, Chief Executive Officer                  Tel: +44 (0)28 9040 6500

 Nick Roberts, Chief Financial Officer                  investorrelations@diaceutics.com

 Susanne Munksted, Chief Precision Medicine Officer

 Stifel Nicolaus Europe Limited (Nomad & Broker)        Tel: +44 (0)20 7710 7600
 Ben Maddison
 Nick Harland
 Kate Hanshaw

 Alma Strategic Communications                          Tel: +44(0)20 3405 0205
 Caroline Forde                                         diaceutics@almastrategic.com

 Kinvara Verdon

 Kieran Breheny

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact their
disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end
commercialisation solution for precision medicines through data analytics,
scientific and advisory services enabled by our platform DXRX - The
Diagnostics Network ®.

About ASCO

The ASCO Annual Meeting represents the world's largest gathering of oncology
physicians, biotechnology executives, researchers, and investment analysts to
discuss cutting-edge clinical research and therapeutics in oncology. This
year, ASCO received and reviewed more than 7,000 abstracts for its Annual
Meeting, ultimately selecting the final entries to be presented on a set of
criteria including the strength and relevance of the research and whether it
addresses an important and novel question.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSEFEFWELSESI